Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-24T12:13:43.580Z Has data issue: false hasContentIssue false
  • English
  • Français

Management of impulse control disorders in Parkinson's disease

Published online by Cambridge University Press:  04 July 2016

Susan Zhang ,
Nadeeka N. Dissanayaka ,
Andrew Dawson Open the ORCID record for Andrew Dawson [Opens in a new window] ,
John D. O'Sullivan ,
Philip Mosley ,
Wayne Hall  and
Adrian Carter
Susan Zhang
Affiliation:
UQ Centre for Clinical Research, The University of Queensland, Queensland, Australia School of Medicine, The University of Queensland, Herston, Queensland, Australia
Nadeeka N. Dissanayaka
Affiliation:
UQ Centre for Clinical Research, The University of Queensland, Queensland, Australia The Neurology Research Centre, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia School of Psychology, The University of Queensland, Queensland, Australia
Andrew Dawson
Affiliation:
School of Psychological Sciences, Monash University, Victoria, Australia
John D. O'Sullivan
Affiliation:
The Neurology Research Centre, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia School of Medicine, The University of Queensland, Herston, Queensland, Australia
Philip Mosley
Affiliation:
School of Medicine, The University of Queensland, Herston, Queensland, Australia Asia-Pacific Centre for Neuromodulation, Queensland Brain Institute, St Lucia, Queensland, Australia Systems Neuroscience Group, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
Wayne Hall
Affiliation:
Centre for Youth Substance Abuse Research, The University of Queensland, Queensland, Australia
Adrian Carter*
Affiliation:
UQ Centre for Clinical Research, The University of Queensland, Queensland, Australia School of Psychological Sciences, Monash University, Victoria, Australia
*
Correspondence should be addressed to: Adrian Carter, Senior Research Fellow, Brain & Mental Health Laboratory, School of Psychological Sciences, Monash University, 770 Blackburn Rd, Monash University, Clayton VIC 3800, Australia. Phone: +61 3 9902 9431. Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Impulse control disorders (ICDs) have become a widely recognized non-motor complication of Parkinson's disease (PD) in patients taking dopamine replacement therapy (DRT). There are no current evidence-based recommendations for their treatment, other than reducing their dopaminergic medication.

Methods:

This study reviews the current literature of the treatment of ICDs including pharmacological treatments, deep brain stimulation, and psychotherapeutic interventions.

Results:

Dopamine agonist withdrawal is the most common and effective treatment, but may lead to an aversive withdrawal syndrome or motor symptom degeneration in some individuals. There is insufficient evidence for all other pharmacological treatments in treating ICDs in PD, including amantadine, serotonin selective reuptake inhibitors, antipsychotics, anticonvulsants, and opioid antagonists (e.g. naltrexone). Large randomized control trials need to be performed before these drugs can be routinely used for the treatment of ICDs in PD. Deep brain stimulation remains equivocal because ICD symptoms resolve in some patients after surgery but may appear de novo in others. Cognitive behavioral therapy has been shown to improve ICD symptoms in the only published study, although further research is urgently needed.

Conclusions:

Further research will allow for the development of evidence-based guidelines for the management of ICDs in PD.

Keywords

Parkinson's diseaseimpulse control disorderspsychopharmacologydeep brain stimulationcognitive behavioral therapy
Type
Review Article
Information
International Psychogeriatrics , Volume 28 , Issue 10 , October 2016 , pp. 1597 - 1614
Copyright
Copyright © International Psychogeriatric Association 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Amami, P. et al. (2014). Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. Journal of Neurology, Neurosurgery & Psychiatry, 86, 562–564.Google Scholar
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Publishing.Google Scholar
Armon, C. et al. (1996). Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology, 47, 626–635.Google Scholar
Ardouin, C. et al. (2006). Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Movement Disorders : Official Journal of the Movement Disorder Society, 21, 1941–1946.Google Scholar
Ardouin, C. et al. (2009). Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease. Revue Neurologique, 165, 845–856.Google Scholar
Barone, P. et al. (2010). Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 9, 573–580.Google Scholar
Bermejo, P. E. (2008). Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism and Related Disorders, 14, 448–449.Google Scholar
Bermejo, P. E., Ruiz-Huete, C. and Anciones, B. (2010). Zonisamide in managing impulse control disorders in Parkinson's disease. Journal of Neurology, 257, 1682–1685.Google Scholar
Bortolato, M., Cannas, A., Solla, P., Bini, V., Puligheddu, M. and Marrosu, F. (2012). Finasteride attenuates pathological gambling in patients with Parkinson disease. Journal of Clinical Psychopharmacology, 32, 424–425.Google Scholar
Broen, M., Duits, A., Visser-Vandewalle, V., Temel, Y. and Winogrodzka, A. (2011). Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism and Related Disorders, 17, 413–417.Google Scholar
Callesen, M. B., Scheel-Kruger, J., Kringelbach, M. L. and Moller, A. (2013). A systematic review of impulse control disorders in Parkinson's disease. Journal of Parkinson's Disease, 3, 105–138.Google Scholar
Cavanagh, J. F. et al. (2011). Subthalamic nucleus stimulation reverses mediofrontal influence over decision threshold. Nature Neuroscience, 14, 1462–1467.Google Scholar
Connolly, B. S. and Fox, S. H. (2012). Drug treatments for the neuropsychiatric complications of Parkinson's disease. Expert Review of Neurotherapeutics, 12, 1439–1449.Google Scholar
Crosby, N. J., Deane, K. H. and Clarke, C. E. (2003). Amantadine for dyskinesia in Parkinson's disease. Cochrane Database of Systematic Reviews, 2, CD003467.Google Scholar
Dagher, A. and Robbins, T. W. (2009). Personality, addiction, dopamine: insights from Parkinson's disease. Neuron, 61, 502–510.Google Scholar
Delaney, M., Leroi, I., Simpson, J. and Overton, P. G. (2012). Impulse control disorders in Parkinson's disease: a psychosocial perspective. Journal of Clinical Psychology in Medical Settings, 19, 338–346.Google Scholar
Dodd, M. L., Klos, K. J., Bower, J. H., Geda, Y. E., Josephs, K. A. and Ahlskog, J. E. (2005). Pathological gambling caused by drugs used to treat Parkinson disease. Archives of Neurology, 62, 1377–1381.Google Scholar
Doll, B. B. and Frank, M. J. (2009). Chapter 19 - The basal ganglia in reward and decision making: computational models and empirical studies. In Dreher, J.-C. and Tremblay, L. (eds.), Handbook of Reward and Decision Making (pp. 399–425). New York: Academic Press.Google Scholar
Eusebio, A. et al. (2013). Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 84, 868–874.Google Scholar
Evans, A. H. et al. (2004). Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Movement Disorders: Official Journal of the Movement Disorder Society, 19, 397–405.Google Scholar
Fernandez, H. H. and Durso, R. (1998). Clozapine for dopaminergic-induced paraphilias in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 13, 597–598.Google Scholar
Frank, M. J., Samanta, J., Moustafa, A. A. and Sherman, S. J. (2007). Hold your horses: impulsivity, deep brain stimulation, and medication in Parkinsonism. Science, 318, 1309–1312.Google Scholar
Gee, L. et al. (2015). The influence of bilateral subthalamic nucleus deep brain stimulation on impulsivity and prepulse inhibition in Parkinson's disease patients. Stereotactic and Functional Neurosurgery, 93, 265–270.Google Scholar
Gerlach, M., Double, K., Arzberger, T., Leblhuber, F., Tatschner, T. and Riederer, P. (2003). Dopamine receptor agonists in current clinical use: comparative receptor binding profiles defined in the human striatum. Journal of Neural Transmission, 110, 1119–1127.Google Scholar
Grant, J. E., Kim, S. W. and Odlaug, B. L. (2007). N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biological Psychiatry, 62, 652–657.Google Scholar
Grant, J. E., Odlaug, B. L., Potenza, M. N., Hollander, E. and Kim, S. W. (2010). Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. The British Journal of Psychiatry: The Journal of Mental Science, 197, 330–331.Google Scholar
Green, N., Bogacz, R., Huebl, J., Beyer, A. K., Kuhn, A. A. and Heekeren, H. R. (2013). Reduction of influence of task difficulty on perceptual decision making by STN deep brain stimulation. Current Biology, 23, 1681–1684.Google Scholar
Gurevich, E. V. and Joyce, J. N. (1999). Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons. Neuropsychopharmacology, 20, 60–80.Google Scholar
Halbig, T. D. et al. (2009). Subthalamic deep brain stimulation and impulse control in Parkinson's disease. European Journal of Neurology, 16, 493–497.Google Scholar
Hardwick, A., Ward, H., Hassan, A., Romrell, J. and Okun, M. S. (2013). Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease. Neurocase, 19, 587–591.Google Scholar
Haynes, W. I. and Haber, S. N. (2013). The organization of prefrontal-subthalamic inputs in primates provides an anatomical substrate for both functional specificity and integration: implications for Basal Ganglia models and deep brain stimulation. Journal of Neuroscience, 33, 4804–4814.Google Scholar
Hershey, T., Revilla, F. J., Wernle, A., Gibson, P. S., Dowling, J. L. and Perlmutter, J. S. (2004). Stimulation of STN impairs aspects of cognitive control in PD. Neurology, 62, 1110–1114.Google Scholar
Hicks, C. W., Pandya, M. M., Itin, I. and Fernandez, H. H. (2011). Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. Parkinsonism & Related Disorders, 17, 379–381.Google Scholar
Hollander, E., DeCaria, C. M., Finkell, J. N., Begaz, T., Wong, C. M. and Cartwright, C. (2000). A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biological Psychiatry, 47, 813–817.Google Scholar
Ivanco, L. S. and Bohnen, N. I. (2005). Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. American Journal of Therapeutics, 12, 467–468.Google Scholar
Kehagia, A. A. et al. (2014). Targeting impulsivity in Parkinson's disease using atomoxetine. Brain, 137, 1986–1997.Google Scholar
Kurlan, R. (2004). Disabling repetitive behaviors in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 19, 433–437.Google Scholar
Lambert, C. et al. (2012). Confirmation of functional zones within the human subthalamic nucleus: patterns of connectivity and sub-parcellation using diffusion weighted imaging. Neuroimage, 60, 83–94.Google Scholar
Lee, J. Y., Kim, H. J. and Jeon, B. S. (2011). Is pathological gambling in Parkinson's disease reduced by amantadine? Annals of Neurology, 69, 213–214; author reply 214–215.Google Scholar
Lhommee, E. et al. (2012). Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain, 135, 1463–1477.Google Scholar
Liang, J. W., Shanker, V. L. and Groves, M. (2015). Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology, 84, 1386–1387.Google Scholar
Lim, S. Y., Evans, A. H. and Miyasaki, J. M. (2008). Impulse control and related disorders in Parkinson's disease: review. Annals of the New York Academy of Sciences, 1142, 85–107.Google Scholar
Lim, S. Y. et al. (2009). Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. Journal of Clinical Neuroscience, 16, 1148–1152.Google Scholar
Lu, C., Bharmal, A. and Suchowersky, O. (2006). Gambling and Parkinson disease. Archives of Neurology, 63, 298.Google Scholar
Macphee, G. J., Chaudhuri, K. R., David, A. S., Worth, P. and Wood, B. (2013). Managing impulse control behaviours in Parkinson's disease: practical guidelines. British Journal of Hospital Medicine, 74, 160–166.Google Scholar
Macphee, G. J., Copeland, C., Stewart, D., Grosset, K. and Grosset, D. G. (2009). Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. Movement Disorders : Official Journal of the Movement Disorder Society, 24, 2430–2431.Google Scholar
Mamikonyan, E. et al. (2008). Long-term follow-up of impulse control disorders in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 23, 75–80.Google Scholar
McElroy, S. L., Keck, P. E. Jr., Pope, H. G. Jr., Smith, J. M. and Strakowski, S. M. (1994). Compulsive buying: a report of 20 cases. Journal of Clinical Psychiatry, 55, 242–248.Google Scholar
Mestre, T. A., Strafella, A. P., Thomsen, T., Voon, V. and Miyasaki, J. (2013). Diagnosis and treatment of impulse control disorders in patients with movement disorders. Therapeutic Advances in Neurological Disorders, 6, 175–188.Google Scholar
Moum, S. J. et al. (2012). Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One, 7, e29768.Google Scholar
Nirenberg, M. (2013). Dopamine agonist withdrawal syndrome: implications for patient care. Drugs & Aging, 30, 587–592.Google Scholar
Nirenberg, M. J. and Waters, C. (2006). Compulsive eating and weight gain related to dopamine agonist use. Movement Disorders : Official Journal of the Movement Disorder Society, 21, 524–529.Google Scholar
Obeso, I. et al. (2011). Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Experimental Brain Research, 212, 371–384.Google Scholar
Okai, D., Askey-Jones, S., Samuel, M., David, A. S. and Brown, R. G. (2015). Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 30, 736–739.Google Scholar
Okai, D. et al. (2013). Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology, 80, 792–799.Google Scholar
Papay, K. et al. (2014). Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology, 83, 826–833.Google Scholar
Parkinson Study Group. (1997). Safety and efficacy of pramipexole in early Parkinson disease. JAMA, 278, 125–130.Google Scholar
Rabinak, C. A. and Nirenberg, M. J. (2010). Dopamine agonist withdrawal syndrome in Parkinson disease. Archives of Neurology, 67, 58–63.Google Scholar
Rotondo, A., Bosco, D., Plastino, M., Consoli, A. and Bosco, F. (2010). Clozapine for medication-related pathological gambling in Parkinson disease. Movement Disorders : Official Journal of the Movement Disorder Society, 25, 1994–1995.Google Scholar
Ruggieri, S., De, P. M. F., Bonamartini, A., Vacca, L. and Stocchi, F. (1997). Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clinical Neuropharmacology, 20, 204–209.Google Scholar
Schneider, C., Corrigall, R., Hayes, D., Kyriakopoulos, M. and Frangou, S. (2013). Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia. European Psychiatry: The Journal of the Association of European Psychiatrists, 29, 1–10.Google Scholar
Schreiber, L., Odlaug, B. L. and Grant, J. E. (2011). Impulse control disorders: updated review of clinical characteristics and pharmacological management. Front Psychiatry, 2, 1.Google Scholar
Schuepbach, W. M. et al. (2013). Neurostimulation for Parkinson's disease with early motor complications. New England Journal of Medicine, 368, 610–622.Google Scholar
Seppi, K. et al. (2011). The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 26 (Suppl. 3), S42–S80.Google Scholar
Sevincok, L., Akoglu, A. and Akyol, A. (2007). Quetiapine in a case with Parkinson disease and pathological gambling. Journal of Clinical Psychopharmacology, 27, 107–108.Google Scholar
Shotbolt, P. et al. (2012). Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. Parkinsonism & Related Disorders, 18, 10–16.Google Scholar
Silberstein, P. et al. (2009). Deep brain stimulation for Parkinson's disease: Australian referral guidelines. Journal of Clinical Neuroscience, 16, 1001–1008.Google Scholar
Smeding, H. M., Goudriaan, A. E., Foncke, E. M., Schuurman, P. R., Speelman, J. D. and Schmand, B. (2007). Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. Journal of Neurology Neurosurgery & Psychiatry, 78, 517–519.Google Scholar
Sokoloff, P., Giros, B., Martes, M. P., Bouthenet, M. L. and Schwartz, J. C. (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347, 146–151.Google Scholar
Sohtaoglu, M., Demiray, D. Y., Kenangil, G., Ozekmekci, S. and Erginoz, E. (2010). Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism & Related Disorders, 16, 334–337.Google Scholar
Thibaut, F., De, L. B. F., Gordon, H., Cosyns, P. and Bradford, J. M. (2010). The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry, 11, 604–655.Google Scholar
Thobois, S. et al. (2007). STN stimulation alters pallidal-frontal coupling during response selection under competition. Journal of Cerebral Blood Flow and Metabolism, 27, 1173–1184.Google Scholar
Thobois, S. et al. (2010). Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain: A Journal of Neurology, 133, 1111–1127.Google Scholar
Thomas, A., Bonanni, L., Gambi, F., Di Iorio, A. and Onofrj, M. (2010). Pathological gambling in Parkinson disease is reduced by amantadine. Annals of Neurology, 68, 400–404.Google Scholar
Trosch, R. M. et al. (1998). Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Movement Disorders: Official Journal of the Movement Disorder Society, 13, 377–382.Google Scholar
Voon, V. et al. (2006). Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology, 67, 1254–1257.Google Scholar
Voon, V. et al. (2007). Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Archives of Neurology, 64, 212–216.Google Scholar
Voon, V. et al. (2011). Impulse control disorders in Parkinson disease: a multicenter case control study. Annals of Neurology, 69, 986–996.Google Scholar
Walsh, R. A. and Lang, A. E. (2012). Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. Movement Disorders: Official Journal of the Movement Disorder Society, 27, 326.Google Scholar
Weintraub, D. (2008). Dopamine and impulse control disorders in Parkinson's disease. Annals of Neurology, 64 (Suppl. 2), S93–S100.Google Scholar
Weintraub, D. et al. (2006). Association of dopamine agonist use with impulse control disorders in Parkinson disease. Archives of Neurology, 63, 969–973.Google Scholar
Weintraub, D. et al. (2010a). Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology, 67, 589–595.Google Scholar
Weintraub, D. et al. (2010b). Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Annals of Neurology, 68, 963–968.Google Scholar
Witt, K. et al. (2004). Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease. Archives of Neurology, 61, 697–700.Google Scholar